Melarsoprol

Gel meat products are important in the meat market. To develop high-quality meat gel products, mannosylerythritol lipid-A (MEL-A) was added to chicken and beef gels, and their physicochemical and biological properties of the composite gel formed by heating were determined in this study. The results of texture analysis showed that MEL-A could significantly improve the hardness, gumminess and chewiness of meat gels and reduce water loss (P < 0.05). In addition, rheological and differential scanning calorimetry (DSC) analysis showed that MEL-A not only improved the rheological properties of meat gel, but also improved its thermal stability. The results of dynamic rheological analysis also showed that MEL-A improved the gel strength of meat gel, and the gel strength of chicken was the highest after adding 1.5 % MEL-A while the gel strength of beef was the highest after adding 2 % MEL-A. The image of scanning electron microscopy (SEM) and protein molecular weight distribution measurement indicated that MEL-A induced protein aggregation, resulting in fewer pores in the meat gels and a more compact network structure. These results suggest that different meat gels show good gel properties, so MEL-A has a lot of potential for gel product development.

Objectives: Primary graft failure (pGF) after hematopoietic stem-cell transplant is associated with considerable morbidity and mortality. The incidence in haplo-HSCT has been reported to be between 0% and 30%. In 2018, we identified a pGF incidence of 35% in our pediatric haplo-HSCT recipients with hematologic malignancies, which motivated us to enact changes to the conditioning regimen.Methods: We performed a single-center prospective, pre-post study of consecutive patients under 16 years with hematologic malignancies, from January 2015 to December 2022 who received a haplo-HSCT. Twenty-six pediatric patients received a haplo-HSCT before September 2018 (G1) and 36 patients after (G2). The main conditioning regimen for G1 was myeloablative with Flu/Cy/Bu, and for G2 the main regimen was reduced intensity Flu/Cy/Mel/TBI2.Results: Nine patients (35%) in G1 had primary graft failure, while in G2 there were no patients with pGF. The median follow-up for G1 was 15.9 months, and for G2 was 24.8 months, with an estimated overall survival at 12 months of 63% (95% CI 47-76) versus 85% (95% CI 73-93), and at 24 months of 47% (95% CI 31-64) versus 70% (95% CI 54-82) respectively (p = .007).Conclusion: After September 2018 conditioning regimen modifications were implemented with the objective of reducing primary failure, consisting mainly of switching from busulfan to melphalan as the alkylating agent of choice, and adding, when clinically possible TBI. Primary failure has been significantly reduced in our institution since then.